6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.

      Cancer Chemotherapy and Pharmacology

      Adult, Antineoplastic Combined Chemotherapy Protocols, blood, therapeutic use, Area Under Curve, Brain Neoplasms, drug therapy, secondary, Carcinoma, Small Cell, secretion, Catheters, Indwelling, Chromatography, High Pressure Liquid, Etoposide, administration & dosage, Humans, Infusions, Intravenous, Lung Neoplasms, pathology, Razoxane

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide. Etoposide plasma levels were determined by HPLC. The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses. The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.

          Related collections

          Author and article information

          Journal
          14574459
          10.1007/s00280-003-0711-z

          Comments

          Comment on this article